Hospira Launches First Biosimilar Monoclonal Antibody for Adult & Pediatric Crohn’s, Ulcerative Colitis In Europe

Hospira Launches First Biosimilar Monoclonal Antibody for Adult & Pediatric Crohn’s, Ulcerative Colitis In Europe
Hospira, Inc., a biotechnology company developing biosimilar therapies, has recently announced the launch of Inflectra (infliximab), the first biosimilar monoclonal antibody (mAb), in major European markets. Inflectra is licensed to address several inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, adult and pediatric Crohn’s disease, and adult and pediatric ulcerative colitis. The company claims that while the lives of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *